Gluten-containing grain allergen labeling

Full Title:
FASTER Act of 2026

Summary#

This bill changes federal food law to treat barley, rye, and oats the same way the law already treats wheat for allergen labeling. It replaces the word “wheat” with “gluten-containing grain” and defines that term to include wheat, rye, barley, oats, and crossbred hybrids (for example, triticale). The bill also directs the Food and Drug Administration (FDA) to update its compliance guidance and asks the Department of Health and Human Services (HHS) for a report on celiac disease.

  • Main change: “Wheat” in the law becomes “gluten-containing grain,” which explicitly lists wheat, rye, barley, and oats.
  • Labeling rule update: FDA must revise its guidance on major food allergens within 1 year.
  • When it starts: The change applies to foods introduced into interstate commerce one year after the law is enacted.
  • Celiac research/report: HHS must report within 1 year on celiac disease surveillance, diagnostics, prevention, risk reduction, and therapies.
  • Scope: The change covers the legal definition of a major food allergen under the Federal Food, Drug, and Cosmetic Act.

What it means for you#

  • Packaged-food makers and importers

    • Must treat barley, rye, and oats as major food allergens the same way they treat wheat. This could mean listing those grains clearly on ingredient labels or allergen statements for products shipped across state lines after the one-year deadline.
    • Must follow updated FDA guidance once it is published.

  • Retailers and grocery stores

    • May receive products with new labels that list these grains more specifically. Stores that repackage or relabel foods may need to change their practices.

  • Restaurants and food service

    • Federal allergen labeling rules apply mainly to packaged foods. The bill does not directly change federal rules that require restaurants to post ingredient labels. Local or state rules for restaurants are not changed by this bill.

  • People with food allergies or celiac disease

    • The bill is meant to make it clearer which grains are considered major allergens under federal law. This could help people who must avoid certain grains to reduce the risk of exposure from packaged foods.
    • HHS will study celiac disease more closely and report on diagnostics and treatments, which could lead to better information or future policy actions.

  • Food manufacturers of gluten-free products

    • The bill changes the allergen list but does not itself change existing gluten-free labeling rules. It could, however, affect how ingredients are declared on packages that claim to be gluten-free. The exact effect is not clearly explained in the bill.

Expenses#

No direct public cost estimate is provided in the bill text or the materials supplied.

  • No publicly available fiscal note or budget estimate was supplied.
  • Possible business costs (not estimated in the bill) include label redesign, updated testing or quality controls, and changes to manufacturing to prevent cross-contact.
  • FDA may incur costs to revise guidance; HHS will carry out a report on celiac disease. The bill does not specify funding for those tasks.

Proponents' View#

The bill appears intended to reduce confusion and increase safety for people who must avoid certain grains by:

  • Making the law’s allergen list clearer by grouping wheat with other gluten-containing grains.
  • Bringing barley, rye, and oats under the same allergen rules as wheat so those ingredients are clearly identified on food labels.
  • Prompting the FDA to update its guidance so industry and enforcement officials have current instructions.
  • Requiring an HHS report to improve knowledge about celiac disease, including surveillance, diagnostics, prevention, and treatment options.

Opponents' View#

Possible concerns or implementation questions raised by the bill’s design include:

  • One concern is cost and burden on food manufacturers. Firms may need to change labels, update testing, or alter production to meet the new labeling practice, but the bill gives no cost estimate or funding support.
  • The bill does not clearly explain how this change will interact with existing “gluten-free” labeling rules. It is unclear whether the definition of “gluten-containing grain” will affect how gluten-free claims are evaluated.
  • Including oats may raise questions because some people with celiac disease tolerate uncontaminated oats but not others. The bill does not distinguish among forms or contamination status of oats.
  • The required FDA guidance revision and the HHS report must happen within 1 year. It is unclear whether that timeline is sufficient or how those agencies will be funded to complete the work.
  • The bill defines crossbred hybrids (for example, triticale) as included, which could create technical labeling or testing issues that the bill does not detail.

If you want, I can pull up the exact bill text or draft plain-language label examples showing how ingredient lists might change.